Open AccessOvercoming Resistance in a BRAF V600e–Mutant Adenocarcinoma of the Lung
Author(s) -
Thomas Schmid,
Martin Buess
Publication year - 2018
Publication title -
current oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.053
H-Index - 51
eISSN - 1718-7729
pISSN - 1198-0052
DOI - 10.3747/co.25.3936
Subject(s) - dabrafenib , trametinib , vemurafenib , medicine , adenocarcinoma , v600e , mutation , cancer research , melanoma , mutant , oncology , cancer , metastatic melanoma , biology , mapk/erk pathway , gene , genetics , kinase
We report on a patient with an adenocarcinoma of the lung harbouring a BRAF V600E mutation who benefited from combination therapy with dabrafenib–trametinib after developing resistance to vemurafenib. To our knowledge, our report shows, for the first time, that combination therapy with dabrafenib–trametinib can overcome vemurafenib resistance in a BRAF V600E–mutated adenocarcinoma of the lung.